BDX
Premium GrowerAI screen passBecton, Dickinson and Company · Healthcare · United States · $54.2B cap · $392.1M/day traded
$214.52 +0.9% · close 11 Nov · scored 12 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 12 Nov 2026, the MoatMap Score for Becton, Dickinson and Company (BDX) is 87/100, ranked against 25,000+ stocks in 38 markets (Quality 52, Value 47, Momentum 88, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Becton Dickinson clears the calibrated bar. All three legs are above the floor (Q56 V67 M60) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure on file is selling that rounds to 0.00% of shares outstanding, which the framework treats as unusable rather than adverse, and there is no negative earnings revision. Medical device demand is defensive, with a large recurring consumables base insulated from the squeezed-consumer theme.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT BECTON, DICKINSON AND COMPANY
Read
Becton, Dickinson and Company (BD) is a global medical technology company developing, manufacturing, and selling medical devices, instrument systems, and reagents. BD is a market leader in critical healthcare segments like medication management, infection prevention, and diagnostic systems, supported by a vast intellectual property portfolio and global distribution. It is a highly diversified and essential supplier to the global healthcare industry, known for its broad product portfolio and significant installed base.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.9B | 19.4B | 20.2B | 21.8B | 5.0% | 19.5B | 22.1B | 23.0B | 1.8% |
| EPS | 5.93 | 4.97 | 5.96 | 5.83 | -0.6% | 5.06 | 6.11 | 6.51 | 3.7% |
| Shares | 283.4M | 290.4M | 289.1M | 285.4M | +0.7% | 272.4M | — | — | — |
| Debt | 16.1B | 15.9B | 20.1B | 19.2B | 6.1% | 16.3B | — | — | — |
| Equity | 25.3B | 25.8B | 25.9B | 25.4B | 0.1% | — | — | — | — |
| Op CF | 2.6B | 3.0B | 3.8B | 3.4B | 9.2% | 3.4B | — | — | — |
| Inv CF | -3.2B | -716.0M | -5.5B | -818.0M | — | — | — | — | — |
| Fin CF | -591.0M | -2.0B | 2.1B | -3.6B | — | — | — | — | — |
Above its 200-day average and 1% below its 52-week high.
Calmer than 80% of stocks we rank over the past year (volatility 27% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDX are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| BDX | Becton, Dickinson and Company(you) | $54.2B | 87 |
| RMD | ResMed Inc. | $35.6B | 88 |
| 7741.T | HOYA Corporation | $55.3B | 75 |
| WST | West Pharmaceutical Services, Inc. | $27.6B | 81 |
| COLO-B.CO | Coloplast A/S | $16.4B | 87 |
| STMN.SW | Straumann Holding AG | $19.1B | 77 |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $16.4B | 79 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| DIM.PA | Sartorius Stedim Biotech S.A. | $23.0B | 66 |
| ISRG | Intuitive Surgical, Inc. | $159.8B | 68 |
Peer medians: ROE 3.0% · P/E 23.0x · Gross margin 53.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.